Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling

BACKGROUND: Glioblastoma, the most common and malignant glial tumor, often has poor prognosis. Tivantinib has shown its potential in treating c-Met-high carcinoma. No studies have explored whether tivantinib inhibits the development of glioblastoma. MATERIAL/METHODS: The correlation between c-Met ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yukun, Li, Zhizhang, Zhang, Lijuan, Liu, Guiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790099/
https://www.ncbi.nlm.nih.gov/pubmed/31575848
http://dx.doi.org/10.12659/MSM.919319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790099/
https://www.ncbi.nlm.nih.gov/pubmed/31575848
http://dx.doi.org/10.12659/MSM.919319

Ejemplares similares